Q4 Earnings Forecast for SLNO Issued By Lifesci Capital

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Lifesci Capital issued their Q4 2024 EPS estimates for Soleno Therapeutics in a research report issued to clients and investors on Tuesday, February 4th. Lifesci Capital analyst M. Belghiti anticipates that the company will earn ($0.37) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q1 2025 earnings at ($1.67) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.32) EPS, Q1 2026 earnings at ($1.55) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at $5.58 EPS, FY2028 earnings at $9.47 EPS and FY2029 earnings at $9.99 EPS.

Several other analysts also recently issued reports on the stock. Robert W. Baird reaffirmed an “outperform” rating and issued a $72.00 price target on shares of Soleno Therapeutics in a report on Monday, December 2nd. Oppenheimer upped their target price on Soleno Therapeutics from $65.00 to $73.00 and gave the company an “outperform” rating in a research note on Monday, October 28th. Stifel Nicolaus reissued a “buy” rating and set a $74.00 price target on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $71.20.

Soleno Therapeutics Trading Up 2.5 %

Shares of NASDAQ SLNO opened at $51.03 on Thursday. The company’s 50-day moving average price is $47.42 and its 200 day moving average price is $49.81. Soleno Therapeutics has a 52 week low of $36.61 and a 52 week high of $60.92. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -15.37 and a beta of -1.46.

Soleno Therapeutics (NASDAQ:SLNO) last posted its earnings results on Wednesday, November 6th. The company reported ($1.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($1.22).

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. US Bancorp DE acquired a new stake in shares of Soleno Therapeutics in the fourth quarter worth $34,000. Avanza Fonder AB purchased a new stake in Soleno Therapeutics during the 4th quarter worth $76,000. Avior Wealth Management LLC acquired a new stake in Soleno Therapeutics in the 4th quarter valued at $89,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Soleno Therapeutics in the third quarter valued at about $155,000. Finally, Curi RMB Capital LLC acquired a new position in shares of Soleno Therapeutics during the third quarter worth about $202,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO James H. Mackaness sold 4,083 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $185,409.03. Following the transaction, the chief financial officer now directly owns 115,089 shares in the company, valued at $5,226,191.49. This represents a 3.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bhatnagar Anish sold 10,937 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $496,649.17. Following the completion of the sale, the chief executive officer now owns 708,616 shares of the company’s stock, valued at approximately $32,178,252.56. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,360 shares of company stock valued at $790,119 in the last quarter. 12.30% of the stock is currently owned by company insiders.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.